David Sinclair on the Longevity Pill, Age Reversal Timelines, and Updated Protocols (Moonshots EP #249)

Why this is in the vault

Filed for three specific load-bearing claims, not the Sinclair-on-supplements baseline (which the vault already has from earlier longevity coverage): (1) the OSK first-in-human eye trial is days away — 2026 becomes the year the partial-reprogramming bet either generates a real signal or doesn’t, which is a Sanity Check Data Dots watch; (2) the Diamandis/Fountain-Life claim that HbA1c outranks LDL and Lp(a) as a CVD predictor — if true at population scale, it reorients how Sanity Check would write about cardiovascular risk and is itself a research-question candidate; (3) the nattokinase-reverses-arterial-plaque claim is the kind of specific intervention assertion that’s either a vault-grade Data Dot or a debunked supplement marketing line — needs a follow-up cross-check. Sponsor/bias surface is heavy (Sinclair has direct equity in every product he names), so the entry doubles as a worked example of how to file a high-conflict source without taking the recommendations at face value.

Episode summary

Recorded on the Abundance Summit stage, Diamandis interviews Harvard geneticist David Sinclair about the imminent first-in-human trial of his lab’s epigenetic reprogramming gene therapy (the “OSK” three-Yamanaka-factor cocktail) being run by Life Biosciences. Sinclair argues 2026 may be the year humans see proven age reversal in vivo, lays out the path from a $500K-$2M AAV gene therapy to a cents-per-pill small molecule discovered via AI screening, defends “no biological upper limit on lifespan,” fundraises for Friends of Sinclair Lab (a private-funding workaround after his federal grants were cut in the Harvard/White House standoff), and closes with his current personal protocol (resveratrol + NMN + metformin/berberine, plus newer additions like nattokinase). Pure stage interview format — no slides, only Wright-brothers cold-open and Abundance Summit branding.

Key arguments / segments (timestamped)

[00:00-01:00] Cold open / Wright Brothers framing. Sinclair: “this feels like another Wright Brothers moment.” OSK (three Yamanaka factors) about to be injected into a human eye to attempt blindness cure. Effects observed in mice across brain, memory, motor neurons (ALS), immune system, muscle, kidney, liver, skin.
[01:00-02:00] Coffee chat, Abundance Summit framing. Diamandis frames the conversation as an update on the “longevity singularity.”
[02:00-04:00] Life Biosciences OSK trial. Days away from first human dosing. Drug candidate emerged from a 2020 Nature cover paper (“Turning Back Time”). Student Wangloo found three of the four Yamanaka genes (OSK) that reverse aging without dedifferentiating cells into stem cells or causing cancer. Eye chosen because FDA permitted; liver likely next.
[04:00-06:00] Tissue-by-tissue rollout. Sinclair lists labs reproducing the work across joints (cartilage and bone regrowth, paper out last week from another group), brain, immune, muscle, kidney, liver, skin. Diamandis interjects with the load-bearing claim: a true longevity therapeutic must work whole-body, not single-cell-type. FDA forcing tissue-by-tissue rollout for safety.
[06:00-10:00] Cost curve from gene therapy to small molecule. Current AAV gene therapy: roughly $500K-$2M per patient. Sinclair lab since 2017 has been screening billions of molecules in silico via AI to find a cheap small-molecule equivalent. Three-molecule cocktail proof of concept exists; aiming to file IND within “next couple of months” as part of XPRIZE Healthspan competition. Long-term aspiration: metformin-cheap pricing.
[10:00-13:00] Accessibility framing. Diamandis pushes “8 billion people” frame. Sinclair: technology starts wealthy-only and diffuses (Wright Brothers analogy again). Predicts 2026 may be the year age reversal is proven in humans.
[13:00-15:00] Field acknowledgment. Sinclair credits Diamandis and the XPRIZE Healthspan (run by Dr. Jamie Justice) for accelerating his willingness to file IND with the chemical cocktail.
[15:00-17:00] Upper limit on human lifespan? Sinclair: no biological law mandates aging; 122 years is current max but animal kingdom shows much higher; “hundreds, maybe thousands of years” not implausible. Cellular reboot has now been done multiple times in mouse eyes without limit observed.
[17:00-23:00] Friends of Sinclair Lab (FoSL) fundraise. Lab lost ~$2-3M/year in federal funding when Harvard’s grants were cut amid the White House dispute. Diamandis seeded $50K and rallied Moonshots audience; raised ~$6M private annual support, ~70 members. Diamandis attacks the NIH grant model: 10% hit rate, reactive, biased against radical science. FoSL example: a member’s daughter needed kidney; benefactor Brett Blundy funded a project within weeks. Wait list opening; community capped to preserve intimacy.
[23:00-31:00] Sinclair’s personal protocol (page 304 of Lifespan). 15+ year staples: (1) resveratrol with fat/protein for absorption — calls it a sirtuin/SIRT1 activator and now ties sirtuins into the Information Theory of Aging that underpins reprogramming; (2) NMN (nicotinamide mononucleotide); (3) glucose-lowering — metformin 1g/day or berberine as natural alternative. Diamandis adds Fountain Life data: HbA1c is the #1 correlate of heart disease, beating LDL and Lp(a). Newer addition: nattokinase 10,000 units/day — only molecule shown in 1000+ person trials to reverse arterial plaque; takes a year. Sinclair tracks via carotid IMT ultrasound (avoids CT radiation, which his lab has shown accelerates aging). Mostly vegan. Quit alcohol — even one drink/day correlates with smaller brain.
[31:00-32:32] Stress, sleep, social closer. Serena (his wife) credited with breaking his Type-A rumination via meditation. Closes on loneliness as mortality risk: “get a pet, get a partner.”

Notable claims (timestamped)

[00:34] First human OSK trial begins “shortly” — Life Biosciences, glaucoma/blindness target via AAV to the eye.
[03:30] OSK = three of the four Yamanaka factors (Oct4, Sox2, Klf4 — omitting c-Myc to avoid cancer risk and identity loss).
[06:45] Current gene therapy delivery: viral-like particles for eye/liver. Whole-body delivery would need lipid nanoparticles or small molecules.
[06:55] Existing AAV gene therapies cost ~$500K–$2M per patient; Sinclair’s stated goal is to drive cost down aggressively.
[08:30] Six weeks of dosing may be enough to see effect in humans (based on AAV ER100 candidate timeline).
[09:30] AI/ML screening pipeline analyzes whether 92-year-old skin cells can be reprogrammed to behave like 20-year-old cells.
[10:30] Three-molecule cocktail working in animals; planned IND within “next couple of months” tied to XPRIZE Healthspan.
[13:10] “It may be 2026 is the year we learn that age reversal is possible in humans.”
[15:30] Maximum recorded human lifespan: 122 (Jeanne Calment). Sinclair sees “no biological reason” for an upper limit.
[19:30] Friends of Sinclair Lab raised ~$6M annual private support after federal cuts; ~70 members, capped.
[20:20] NIH grants: ~10% acceptance rate, structurally biased against radical hypotheses.
[25:30] Personal stack: resveratrol (with fat) + NMN + metformin 1g/day (or berberine).
[27:20] Diamandis (Fountain Life data): HbA1c is the strongest correlate of heart disease in their longitudinal cohort — stronger than LDL or Lp(a).
[28:30] Nattokinase at 10,000 units/day for 12+ months — only intervention shown in large RCTs (1000+ subjects) to reverse arterial plaque.
[29:30] Sinclair prefers carotid ultrasound IMT over CT scans — his lab has shown medical radiation accelerates aging.
[30:00] Even one alcoholic drink per day correlates with smaller brain volume; Sinclair quit.

Guests

David Sinclair — Professor of Genetics, Harvard Medical School; co-director, Paul F. Glenn Center for Biology of Aging Research. Author of Lifespan: Why We Age and Why We Don’t Have To (2019). Co-founder of Life Biosciences (the company running the OSK eye trial), Tally Health, MetroBiotech (NMN), and others. His 2020 Nature cover paper established that partial epigenetic reprogramming via three Yamanaka factors can reverse cellular age in vivo. Polarizing in the longevity field — admired for the Information Theory of Aging framework, criticized for commercial entanglements (resveratrol/Sirtris saga, NMN supplement promotion). Married to Serena Poon (Sommelier, holistic chef), credited throughout the interview with shaping his diet, alcohol, and stress practices.

Peter Diamandis (host) — XPRIZE founder, Singularity University co-founder, Fountain Life co-founder, Bold and Abundance co-author. Wears “LEV: 2033” (Longevity Escape Velocity 2033) shirt during the interview, signaling Aubrey de Grey-style framing.

Mapping against Ray Data Co

Mapping: medium. This sits in the founder’s longevity/healthspan watch zone but the core science is reasonably well-covered ground for anyone tracking Sinclair. The genuinely new bits:

2026 in-human OSK trial is imminent, not theoretical. Worth flagging in any longevity tracking note — this is the year the partial-reprogramming bet either gets a real signal or doesn’t. Connects to vault’s existing longevity coverage and to the founder-longevity-stack thinking.
HbA1c > LDL/Lp(a) for heart disease risk (Diamandis citing Fountain Life data) is the most actionable nugget here. If true at population scale, it reinforces the metabolic-health-first framing the founder already leans toward and has implications for how Sanity Check would write about cardiovascular risk. Worth a cross-check against the published literature before anchoring to it — Fountain Life is a self-selected concierge cohort and Diamandis has financial incentive to promote glucose-monitoring narratives.
Nattokinase plaque reversal claim is the most surprising specific intervention claim. If validated, it’s a Sanity Check Data Dots candidate. Worth queuing a research question: “Does nattokinase actually reverse arterial plaque in large RCTs, or is the evidence base smaller than Sinclair implies?”
Brain-health overlap with the Tim Ferriss / Wood thread the founder has been mapping: alcohol → smaller brain (Sinclair quit), meditation / stress reduction (Serena’s intervention), social isolation as mortality multiplier (“loneliness will kill you”). All three converge with the brain-health thesis the vault has been building. The Sinclair angle is congruent rather than additive — confirms the direction.
Funding model commentary (FoSL) is interesting independent of the science: Diamandis is publicly attacking NIH’s 10%-hit-rate, anti-radical-science bias and demonstrating a private-membership replacement that funds an experiment “within weeks instead of years.” This is a science-funding-reform data point and a possible Sanity Check angle on “what happens to American basic research when the federal pipeline breaks.” Stronger story than the supplement protocol.

Sponsor/bias flags:

Sinclair has direct financial ties to Life Biosciences (OSK trial), MetroBiotech (NMN), and Tally Health. Every protocol recommendation he makes overlaps with a product he profits from. He flags this himself (“I suffer from my face showing up on people’s websites selling products”) but doesn’t pull the recommendations.
Diamandis is a Life Biosciences investor and runs both XPRIZE Healthspan and Fountain Life — every framing in this episode benefits one of his vehicles.
The episode is also a fundraising pitch for Friends of Sinclair Lab from the Abundance Summit stage. Treat the “everything is going great, 2026 is the year” framing accordingly.

Skip-or-use call: Skip for general listening — Sinclair has been on every longevity podcast saying versions of this for two years. Use for the three specific data points worth chasing: HbA1c-as-top-CVD-correlate, nattokinase plaque reversal, OSK eye trial readout (track for 2026 results).

founder-longevity-stack
cross-check
brain-health
science-funding-reform
Sanity-Check-Data-Dots
2026-04-27-moonshots-sinclair-longevity-pill-transcript